Bank of America
GPCR icon

Bank of America’s Structure Therapeutics GPCR Stock Holding History

Bank of America’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.9M Buy
227,132
+195,454
+617% +$13.4M ﹤0.01% 2881
2025
Q4 		$2.2M Buy
31,678
+17,899
+130% +$731K ﹤0.01% 3991
2025
Q3 		$386K Sell
13,779
-129
-0.9% -$2.57K ﹤0.01% 5948
2025
Q2 		$288K Sell
13,908
-41,530
-75% -$913K ﹤0.01% 6008
2025
Q1 		$960K Buy
55,438
+1,253
+2% +$30.7K ﹤0.01% 5252
2024
Q4 		$1.47M Sell
54,185
-43,206
-44% -$1.53M ﹤0.01% 4706
2024
Q3 		$4.27M Buy
97,391
+13,030
+15% +$504K ﹤0.01% 3885
2024
Q2 		$3.31M Buy
84,361
+46,185
+121% +$1.9M ﹤0.01% 4000
2024
Q1 		$1.64M Sell
38,176
-38,328
-50% -$1.62M ﹤0.01% 4581
2023
Q4 		$3.12M Buy
76,504
+66,630
+675% +$3.82M ﹤0.01% 3962
2023
Q3 		$498K Buy
9,874
+8,190
+486% +$264K ﹤0.01% 5316
2023
Q2 		$70K Buy
+1,684
New +$47.2K ﹤0.01% 6344

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Bank of America's GPCR Position: Q1 2026 in Review

Bank of America increased its Structure Therapeutics (GPCR) stake by 617% in Q1 2026, buying an estimated $13.4M and bringing the position to 227,132 shares worth $10.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2881.

Bank of America first reported a position in GPCR in Q2 2023 and has held it in 12 quarters since. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

  • Bank of America held 227,132 shares of Structure Therapeutics worth $10.9M as of Q1 2026.
  • Bank of America bought 195,454 Structure Therapeutics shares in Q1 2026, an estimated $13.4M.
  • Structure Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #2881 holding.
  • Bank of America first reported a position in Structure Therapeutics in Q2 2023 and has held it in 12 quarters since.
  • 196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.